2024-511711-21-00RecruitingPhase 4
ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
-to assess the safety of surgery in patients with initially unresectable stage III NSCLC who are considered resectable by the multidisciplinary team within 12 weeks after finishing high-dose CRT -to assess the ability to proceed to durvalumab consolidation therapy after surgery
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- First submitted
- 15 Mar 2024
- Start date
- 16 Dec 2024
- Lead sponsor
- Amsterdam UMC Stichting
- Diseases
- Lung cancer
- EU CT number
- 2024-511711-21-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 38
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III non-small cell lung cancer (not N3) who are first planned for chemoradiotherapy followed by durvalumab. It tests whether surgery after chemoradiotherapy is safe.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage III non-small cell lung cancer without N3 disease, confirmed by tissue or cell tests before chemoradiotherapy starts
- Earlier treatment
- The team first advised chemoradiotherapy followed by durvalumab, without surgery. People must not have had chemoradiotherapy schemes other than platinum doublet with 30 once-daily fractions of 2 Gy.
- Biomarker or test result
- If N2 disease is suspected, invasive staging of the mediastinum must prove it before chemoradiotherapy starts. People with known gene changes that can be treated cannot join.
Main reasons for not taking part
- TxN3 or M1 disease
- Chemoradiotherapy schemes other than platinum doublet with 30 once-daily fractions of 2 Gy
- Cannot have surgery because of heart and lung function tests or other illnesses
- Known gene changes that can be treated with targeted drugs
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with TxN3 or M1 disease
Other
- The use of any CRT schemes other than those in ESMO recommendations (platinum doublet, 30 once-daily fractions of 2 Gy)
- Patients deemed inoperable based on cardiopulmonary function tests or comorbidity
- Patients with known actionable genomic alterations.
Who the study is looking for
- Histologically or cytologically confirmed stage III (non-N3) NSCLC (TNM 8th edition), before start of chemoradiotherapy
- In case of suspected N2-disease, mediastinal invasive staging (EUS, EBUS and/or mediastinoscopy) to prove N2 involvement before start of concurrent CRT is mandatory.
- Initial MDT recommendation for a non-surgical treatment comprising CRT followed by durvalumab
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Stichting | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.